Cargando…
Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
OBJECTIVE: To develop and validate a DeepSurv nomogram based on radiomic features extracted from computed tomography images and clinicopathological factors, to predict the overall survival and guide individualized adjuvant chemotherapy in patients with non-small cell lung cancer (NSCLC). PATIENTS AN...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260694/ https://www.ncbi.nlm.nih.gov/pubmed/35814402 http://dx.doi.org/10.3389/fonc.2022.895014 |
_version_ | 1784742094031552512 |
---|---|
author | Yang, Bin Liu, Chengxing Wu, Ren Zhong, Jing Li, Ang Ma, Lu Zhong, Jian Yin, Saisai Zhou, Changsheng Ge, Yingqian Tao, Xinwei Zhang, Longjiang Lu, Guangming |
author_facet | Yang, Bin Liu, Chengxing Wu, Ren Zhong, Jing Li, Ang Ma, Lu Zhong, Jian Yin, Saisai Zhou, Changsheng Ge, Yingqian Tao, Xinwei Zhang, Longjiang Lu, Guangming |
author_sort | Yang, Bin |
collection | PubMed |
description | OBJECTIVE: To develop and validate a DeepSurv nomogram based on radiomic features extracted from computed tomography images and clinicopathological factors, to predict the overall survival and guide individualized adjuvant chemotherapy in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: This retrospective study involved 976 consecutive patients with NSCLC (training cohort, n=683; validation cohort, n=293). DeepSurv was constructed based on 1,227 radiomic features, and the risk score was calculated for each patient as the output. A clinical multivariate Cox regression model was built with clinicopathological factors to determine the independent risk factors. Finally, a DeepSurv nomogram was constructed by integrating the risk score and independent clinicopathological factors. The discrimination capability, calibration, and clinical usefulness of the nomogram performance were assessed using concordance index evaluation, the Greenwood-Nam-D’Agostino test, and decision curve analysis, respectively. The treatment strategy was analyzed using a Kaplan–Meier curve and log-rank test for the high- and low-risk groups. RESULTS: The DeepSurv nomogram yielded a significantly better concordance index (training cohort, 0.821; validation cohort 0.768) with goodness-of-fit (P<0.05). The risk score, age, thyroid transcription factor-1, Ki-67, and disease stage were the independent risk factors for NSCLC.The Greenwood-Nam-D’Agostino test showed good calibration performance (P=0.39). Both high- and low-risk patients did not benefit from adjuvant chemotherapy, and chemotherapy in low-risk groups may lead to a poorer prognosis. CONCLUSIONS: The DeepSurv nomogram, which is based on the risk score and independent risk factors, had good predictive performance for survival outcome. Further, it could be used to guide personalized adjuvant chemotherapy in patients with NSCLC. |
format | Online Article Text |
id | pubmed-9260694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92606942022-07-08 Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer Yang, Bin Liu, Chengxing Wu, Ren Zhong, Jing Li, Ang Ma, Lu Zhong, Jian Yin, Saisai Zhou, Changsheng Ge, Yingqian Tao, Xinwei Zhang, Longjiang Lu, Guangming Front Oncol Oncology OBJECTIVE: To develop and validate a DeepSurv nomogram based on radiomic features extracted from computed tomography images and clinicopathological factors, to predict the overall survival and guide individualized adjuvant chemotherapy in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: This retrospective study involved 976 consecutive patients with NSCLC (training cohort, n=683; validation cohort, n=293). DeepSurv was constructed based on 1,227 radiomic features, and the risk score was calculated for each patient as the output. A clinical multivariate Cox regression model was built with clinicopathological factors to determine the independent risk factors. Finally, a DeepSurv nomogram was constructed by integrating the risk score and independent clinicopathological factors. The discrimination capability, calibration, and clinical usefulness of the nomogram performance were assessed using concordance index evaluation, the Greenwood-Nam-D’Agostino test, and decision curve analysis, respectively. The treatment strategy was analyzed using a Kaplan–Meier curve and log-rank test for the high- and low-risk groups. RESULTS: The DeepSurv nomogram yielded a significantly better concordance index (training cohort, 0.821; validation cohort 0.768) with goodness-of-fit (P<0.05). The risk score, age, thyroid transcription factor-1, Ki-67, and disease stage were the independent risk factors for NSCLC.The Greenwood-Nam-D’Agostino test showed good calibration performance (P=0.39). Both high- and low-risk patients did not benefit from adjuvant chemotherapy, and chemotherapy in low-risk groups may lead to a poorer prognosis. CONCLUSIONS: The DeepSurv nomogram, which is based on the risk score and independent risk factors, had good predictive performance for survival outcome. Further, it could be used to guide personalized adjuvant chemotherapy in patients with NSCLC. Frontiers Media S.A. 2022-06-23 /pmc/articles/PMC9260694/ /pubmed/35814402 http://dx.doi.org/10.3389/fonc.2022.895014 Text en Copyright © 2022 Yang, Liu, Wu, Zhong, Li, Ma, Zhong, Yin, Zhou, Ge, Tao, Zhang and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yang, Bin Liu, Chengxing Wu, Ren Zhong, Jing Li, Ang Ma, Lu Zhong, Jian Yin, Saisai Zhou, Changsheng Ge, Yingqian Tao, Xinwei Zhang, Longjiang Lu, Guangming Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer |
title | Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer |
title_full | Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer |
title_fullStr | Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer |
title_full_unstemmed | Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer |
title_short | Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer |
title_sort | development and validation of a deepsurv nomogram to predict survival outcomes and guide personalized adjuvant chemotherapy in non-small cell lung cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260694/ https://www.ncbi.nlm.nih.gov/pubmed/35814402 http://dx.doi.org/10.3389/fonc.2022.895014 |
work_keys_str_mv | AT yangbin developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT liuchengxing developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT wuren developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT zhongjing developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT liang developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT malu developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT zhongjian developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT yinsaisai developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT zhouchangsheng developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT geyingqian developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT taoxinwei developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT zhanglongjiang developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer AT luguangming developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer |